Cogent Biosciences, (id:7873 COGT)
9.13 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 10:07:41 AM)
Exchange closed, opens in 23 hours 22 minutes
About Cogent Biosciences,
Market Capitalization 1.07B
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
275 Wyman Street Waltham 02451 MA United States |
| Phone | 617 945 5576 |
| Website | https://www.cogentbio.com |
| Employees | 164 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | COGT |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 3.67 - 12.61 |
| Market Capitalization | 1.07B |
| P/E trailing | -3.77 |
| P/E forward | -4.20 |
| Price/Book | 5.22 |
| Beta | 0.021 |
| EPS | -2.49 |
| EPS United States (ID:6, base:3402) | 24.22 |